# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### **SCHEDULE 14A INFORMATION**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Filed by the Registrant $\ oxtimes$		Filed by a Party other than the Registrant $\ \Box$						
Check the appropriate box:								
	Preliminary Proxy Statement							
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))							
	Definitive Proxy Statement							
$\boxtimes$	Definitive Additional Materials							
	Soliciting Material under §240.14a-12							
		SERES THERAPEUTICS, INC. (Name of Registrant as Specified In Its Charter)						
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)								
Payme ⊠ □	nt of Filing Fee (Check all boxes that a No fee required Fee paid previously with prelimina Fee computed on table in exhibit re							



SERES THERAPEUTICS, INC.

2023 Annual Meeting Vote by June 21, 2023 11:59 PM ET



V14200-P88535

#### You invested in SERES THERAPEUTICS, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on June 22, 2023.

## Get informed before you vote

View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 8, 2023. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control#

### Smartphone users

Point your camera here and vote without entering a control number





## Vote Virtually at the Meeting\*

June 22, 2023 8:00 AM EDT

Virtually at: www.virtualshareholdermeeting.com/MCRB2023

<sup>\*</sup>Please check the meeting materials for any special requirements for meeting attendance.

## THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

4. Approval of an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 200,000,000 to 240,000,000.  5. Approval of an adjournment of the Approx Modeling if processing the collection of the Approx Modeling in processing the collection of the Approx Modeling in processing the collection of the Approx Modeling in the collection of the Collec	Board Recommends	
<ul> <li>01) Stephen A. Berenson</li> <li>02) Richard N. Kender</li> <li>03) Claire M. Fraser, Ph.D.</li> <li>2. Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.</li> <li>3. Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers.</li> <li>4. Approval of an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 200,000,000 to 240,000,000.</li> <li>5. Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 4.</li> <li>NOTE: To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or</li> </ul>		
<ul> <li>02) Richard N. Kender</li> <li>03) Claire M. Fraser, Ph.D.</li> <li>2. Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.</li> <li>3. Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers.</li> <li>4. Approval of an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 200,000,000 to 240,000,000.</li> <li>5. Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 4.</li> <li>NOTE: To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or</li> </ul>		
<ol> <li>Claire M. Fraser, Ph.D.</li> <li>Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.</li> <li>Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers.</li> <li>Approval of an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 200,000,000 to 240,000,000.</li> <li>Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 4.</li> <li>NOTE: To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or</li> </ol>	or	
year ending December 31, 2023.  3. Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers.  4. Approval of an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 200,000,000 to 240,000,000.  5. Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 4.  NOTE: To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or		
<ul> <li>4. Approval of an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 200,000,000 to 240,000,000.</li> <li>5. Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 4.</li> <li>NOTE: To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or</li> </ul>	For	
Common Stock from 200,000,000 to 240,000,000.  5. Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 4.  NOTE: To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or	For	
at the time of the Annual Meeting to approve Proposal 4.  NOTE: To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or	For	
	For	